Disease details

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

6 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01910259 (ClinicalTrials.gov)	December 18, 2014	19/7/2013	MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial	A Multi-arm Phase IIB Randomised, Double Blind Placebo-controlled Clinical Trial Comparing the Efficacy of Three Neuroprotective Drugs in Secondary Progressive Multiple Sclerosis.	Secondary Progressive Multiple Sclerosis	Drug: Amiloride;Drug: Riluzole;Drug: Fluoxetine;Drug: Placebo	University College, London	Medical Research Council;National Institute for Health Research, United Kingdom;MS Society;University of Edinburgh;Queen Mary University of London;Keele University;University of Sheffield;University of Leeds;University of Warwick	Completed	25 Years	65 Years	All	445	Phase 2	United Kingdom
2	EUCTR2012-005394-31-GB (EUCTR)	01/04/2014	05/09/2014	MS-SMART: A Trial of Efficacy (usefulness) of 3 Neuroprotective Drugs in SPMS	MS-SMART: A Multi-Arm Phase IIb Randomised, Double Blind Placebo-Controlled Clinical Trial Comparing The Efficacy of Three Neuroprotective Drugs in Secondary Progressive Multiple Sclerosis - MS-SMART: Multiple Sclerosis Secondary Progressive Multi-Arm Randomisation Trial	Mutliple Sclerosis (Secondary Progressive);Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Rilutek Product Name: Rilutek INN or Proposed INN: Riluzole Trade Name: Amiloride Product Name: Amiloride INN or Proposed INN: Amiloride Trade Name: Fluoxetine Product Name: Fluoxetine INN or Proposed INN: Fluoxetine hydrochloride	UCL	NULL	Not Recruiting			Female: yes Male: yes	440	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	United Kingdom
3	EUCTR2011-003775-11-BE (EUCTR)	12/01/2012	07/09/2011	Fluoxetine therapy for multiple sclerosis	Fluoxetine therapy for multiple sclerosis - FLUOX-PMS	progressive multiple sclerosis MedDRA version: 16.0;Level: PT;Classification code 10063401;Term: Primary progressive multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 16.0;Classification code 10063400;Term: Secondary progressive multiple sclerosis;Classification code 10053395;Term: Progressive multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Fluoxetine Product Name: Fluoxetine Product Code: fluoxetine INN or Proposed INN: Fluoxetine Other descriptive name: N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine		NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	120		Belgium
4	NCT01436643 (ClinicalTrials.gov)	November 2011	16/9/2011	Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression	A 21-week, Multicenter, Open Label Study to Evaluate the Safety and Tolerability Profile of the Combination of a SSRI or SNRI Antidepressive Therapy With Oral Fingolimod in the Treatment of RRMS Patients With Mild to Moderate Depression	Depression;Relapsing-remitting Multiple Sclerosis	Drug: Venlafaxine;Drug: Fluoxetine;Drug: Citalopram;Drug: Fingolimod	Novartis Pharmaceuticals	NULL	Terminated	18 Years	65 Years	All	54	Phase 4	Germany
5	EUCTR2010-023996-25-BE (EUCTR)	21/12/2010	25/11/2010	The effect of fluoxetine and 5-HT4 serotonin receptor agonists on cerebral axonal energy metabolism and glutamate levels in multiple sclerosis.	The effect of fluoxetine and 5-HT4 serotonin receptor agonists on cerebral axonal energy metabolism and glutamate levels in multiple sclerosis.	Multiple sclerosis (both relapsing remitting and progressive forms)	Product Name: fluoxetine Other descriptive name: FLUOXETINE Product Name: Cisapride INN or Proposed INN: CISAPRIDE Product Name: Prucalopride INN or Proposed INN: PRUCALOPRIDE		NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	32		Belgium
6	EUCTR2011-001692-39-DE (EUCTR)		08/06/2011	A study to evaluate the safety and tolerability of the combination of an antidepressive therapy with oral fingolimod in the treatment of relapsing remitting multiple sclerosis patients with mild to moderate depression	A 21-week, multicenter, open label study to evaluate the safety and tolerability profile of the combination of a SSRI or SNRI antidepressive therapy with oral fingolimod in the treatment of RRMS patients with mild to moderate depression	Multiple SclerosisDepression MedDRA version: 14.1;Level: PT;Classification code 10012378;Term: Depression;System Organ Class: 10037175 - Psychiatric disorders MedDRA version: 14.1;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Gilenya Product Name: Gilenya Other descriptive name: FINGOLIMOD HYDROCHLORIDE Trade Name: Venlafaxin Hexal Product Name: Venlafaxin Hexal Other descriptive name: VENLAFAXINE HYDROCHLORIDE Trade Name: Fluoxetin Hexal Product Name: Fluoxetin Hexal INN or Proposed INN: FLUOXETINE HYDROCHLORIDE Trade Name: Venlafaxin Hexal Product Name: Venlafaxin Hexal Other descriptive name: VENLAFAXINE HYDROCHLORIDE Trade Name: Fluoxetin Hexal Product Name: Fluoxetin Hexal INN or Proposed INN: FLUOXETINE HYDROCHLORIDE Trade Name: Gilenya Product Name: Gilenya Other descriptive name: FINGOLIMOD HYDROCHLORIDE	Novartis Pharma GmbH	NULL	Not Recruiting			Female: yes Male: yes			Germany

先頭へ